Clinical trials

This study is a phase 3, double-blind, placebo-controlled, multicenter study of ASP3082 for the first-line treatment of participants with metastatic PDAC with KRAS G12D mutation in combination with mFOLFIRINOX or NALIRIFOX. The study will be conducted in approximately 250 study sites across Europe, Asia-Pacific and the Americas. 

The objective of the study is to evaluate efficacy and safety of Zanzalintinib in participants with recurrent or progressive meningioma refractory to standard therapies.

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). The primary objective of this study is to determine whether induction immunotherapy (IO) and chemotherapy prior to concurrent chemoradiation therapy (CCRT) + IO improves progression-free survival (PFS) compared to CCRT+IO alone.

The main purpose of this study is to measure the safety and effectiveness with ivonescimab/SMT112 in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and Fluorouracil) in the first-line treatment of metastatic colorectal cancer (mCRC) compared to bevacizumab in combination with chemotherapy drugs, i.e., FOLFOX (Oxaliplatin, Leucovorin and 5-Fluorouracil). Ivonescimab/SMT112 is considered investigational and has not been approved by the U.S. Food & Drug Administration/local Regulatory Authority for treatment or sale. Bevacizumab is a different approved drug sold under the brand name Avastin. FOLFOX is a standard chemotherapy regimen made up of the drugs folinic acid (leucovorin, FOL), fluorouracil (5-FU, F), and oxaliplatin (Eloxatin, OX).

To determine the efficacy, safety, and tolerability of tafasitamab in participants with primary ITP or primary wAIHA. 

The purpose of this trial is to learn more about how zongertinib  works for people with advanced cancers. The trial drug will be given alone or in combination with other approved anti-cancer drugs, such as trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1), and trastuzumab (with or without capecitabine). 

This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated.

The objective of this study is to evaluate the safety and tolerability of PF-08046033 in participants with advanced solid tumors, identify the maximum tolerated dose (MTD) or maximum administered dose (MAD) of PF-08046033, and identify a recommended dose and schedule of PF-08046033 for expansion (RDE).

The objective is to see if the combination of valproic acid, irinotecan, and simvastatin causes these tumors to stabilize or shrink, which is a sign that these combinations are effective against these tumors.  

The purpose of this study is to gather safety information, meaning the type and frequency of any possible side effects in pregnant women and their infants when the GBS6 is given. This study will also assess the ability of GBS6 to stimulate an immune response by measuring the antibodies against the 6 most common serotypes of GBS.